BRPI0820342A2 - Modulação de tráfego de proteína - Google Patents

Modulação de tráfego de proteína

Info

Publication number
BRPI0820342A2
BRPI0820342A2 BRPI0820342-3A BRPI0820342A BRPI0820342A2 BR PI0820342 A2 BRPI0820342 A2 BR PI0820342A2 BR PI0820342 A BRPI0820342 A BR PI0820342A BR PI0820342 A2 BRPI0820342 A2 BR PI0820342A2
Authority
BR
Brazil
Prior art keywords
protein traffic
traffic modulation
modulation
protein
traffic
Prior art date
Application number
BRPI0820342-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Dan Elbaum
Christine Ellen Bulawa
Michael Devit
Original Assignee
Foldrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foldrx Pharmaceuticals Inc filed Critical Foldrx Pharmaceuticals Inc
Publication of BRPI0820342A2 publication Critical patent/BRPI0820342A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0820342-3A 2007-11-07 2008-11-07 Modulação de tráfego de proteína BRPI0820342A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98628207P 2007-11-07 2007-11-07
PCT/US2008/082909 WO2009062118A2 (en) 2007-11-07 2008-11-07 Modulation of protein trafficking

Publications (1)

Publication Number Publication Date
BRPI0820342A2 true BRPI0820342A2 (pt) 2015-05-26

Family

ID=40521617

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820342-3A BRPI0820342A2 (pt) 2007-11-07 2008-11-07 Modulação de tráfego de proteína

Country Status (10)

Country Link
US (1) US20100331297A1 (enExample)
EP (1) EP2217239A2 (enExample)
JP (1) JP2011503103A (enExample)
CN (1) CN101917999A (enExample)
AU (1) AU2008323694A1 (enExample)
BR (1) BRPI0820342A2 (enExample)
CA (1) CA2705303A1 (enExample)
EA (1) EA201070572A1 (enExample)
WO (1) WO2009062118A2 (enExample)
ZA (1) ZA201003725B (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
ES2570429T3 (es) * 2008-10-16 2016-05-18 Univ California Inhibidores de heteroaril quinasa de anillo condensado
DE102009004245A1 (de) * 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
BRPI1015135B1 (pt) 2009-06-29 2021-08-03 Incyte Holdings Corporation Pirimidinonas inibidoras de pi3k, composição compreendendo tais compostos, bem como usos dos mesmos
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
HUE025177T2 (en) 2009-12-23 2016-02-29 Takeda Pharmaceuticals Co Fused heteroaromatic pyrrolidinones as syk inhibitors
CA2785716A1 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
WO2011094290A1 (en) * 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
KR20120117905A (ko) 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US8642606B2 (en) * 2010-09-29 2014-02-04 Plexxikon Inc. ZAP-70 active compounds
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
EP2701510B1 (en) 2011-04-25 2017-02-15 Usher III Initiative Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
EP2723739B1 (en) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
EP2548878A1 (en) * 2011-07-21 2013-01-23 Laboratorios Del. Dr. Esteve, S.A. Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
DK3513793T3 (da) 2011-09-02 2021-04-26 Incyte Holdings Corp Heterocyclylaminer som pi3k-inhibitorer
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
AU2013334138B2 (en) * 2012-10-25 2017-07-27 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome
JP6291502B2 (ja) * 2012-10-25 2018-03-14 アッシャー・サード・イニシアティブ・インコーポレイテッド ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
SI2958921T1 (sl) 2013-02-22 2017-12-29 Pfizer Inc. Derivati pirolo(2,3-d)pirimidina kot inhibitorji Janus kinaz (JAK)
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
US9695166B2 (en) 2014-05-05 2017-07-04 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
CA2948587C (en) * 2014-05-14 2018-07-17 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
CN104530153A (zh) * 2015-01-15 2015-04-22 佛山市赛维斯医药科技有限公司 一类苯基s-葡萄糖苷衍生物、其制备方法和在医药上的用途
CN104530151A (zh) * 2015-01-15 2015-04-22 佛山市赛维斯医药科技有限公司 一种含硝基苯s-葡萄糖苷结构的化合物及其用途
MX373232B (es) 2015-02-27 2020-05-08 Incyte Holdings Corp Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparación.
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
EP3312182B9 (en) 2015-06-22 2022-06-29 Ono Pharmaceutical Co., Ltd. Brk inhibitory compound
KR102665765B1 (ko) 2015-07-20 2024-05-10 젠자임 코포레이션 콜로니 자극 인자-1 수용체(csf-1r) 저해제
LV15201B (lv) 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts Ibrutiniba izejvielas iegūšanas paņēmiens
CN105198887B (zh) * 2015-09-23 2017-07-28 上海泰坦科技股份有限公司 具有生物活性吡唑并[3,4‑d]嘧啶类试剂的合成工艺
JP6779992B2 (ja) * 2015-10-09 2020-11-04 アッヴィ・エス・ア・エール・エル Ｎ−スルホニル化ピラゾロ［３，４−ｂ］ピリジン−６−カルボキサミドおよび使用法
MX2018004365A (es) * 2015-10-09 2018-08-16 Abbvie Sarl Combinaciones de potenciador-corrector utiles en el tratamiento de fibrosis quistica.
GB201521109D0 (en) * 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
EP3414226A4 (en) * 2016-02-12 2019-12-18 Pharmaxis Ltd. INDOL AND AZAINDOL HALOALLYLAMINE DERIVATIVE INHIBITORS OF LYSYLOXIDASES AND USES THEREOF
DK3416955T3 (da) * 2016-02-15 2020-12-14 Inst Nat Sante Rech Med Anvendelse af stiripentol og derivater deraf til reducering af oxalatkoncentrationen i urin hos et individ
WO2017161344A1 (en) * 2016-03-17 2017-09-21 The Regants Of The University Of California Compositions and methods for treating parasitic diseases
CN107513068A (zh) * 2016-06-16 2017-12-26 中国科学院上海药物研究所 一种具有fgfr抑制活性的新型化合物及其制备和应用
KR20190035925A (ko) 2016-08-24 2019-04-03 아르퀼 인코포레이티드 아미노-피롤로피리미디논 화합물 및 이의 사용 방법
IL248028B (en) * 2016-09-25 2022-02-01 Univ Bar Ilan Wasp-protecting small molecules, preparations containing them and their uses for methods in the treatment of Wiskott-Aldrich syndrome and x-linked thrombocytopenia
KR102585398B1 (ko) * 2016-11-18 2023-10-10 시스틱 파이브로시스 파운데이션 Cftr 강화제로서의 피롤로피리미딘
PT3546457T (pt) * 2016-11-28 2021-08-06 Jiangsu Hengrui Medicine Co Derivado de pirazolo-heteroarílico, método de preparação e a utilização médica do mesmo
CN110300589B (zh) * 2016-12-16 2023-03-10 囊性纤维化基金会 作为cftr增效剂的双环异杂芳基衍生物
TW201837040A (zh) * 2017-03-15 2018-10-16 美商微拉製藥公司 Cdpk1抑制劑及與其相關之組合物及方法
TW201920184A (zh) * 2017-08-17 2019-06-01 美國華盛頓大學 Cdpk1抑制劑、組合物及與其相關之方法
FR3075795A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075794A1 (fr) * 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
CN111630054B (zh) * 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
MX2020012651A (es) * 2018-05-25 2021-02-02 Jiangsu Hengrui Medicine Co Forma de cristal de clorhidrato de derivado de pirazoloheteroarilo, y metodo de preparacion.
CN110526918B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的晶型及制备方法
CN110526917B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法
MA52761A (fr) 2018-06-01 2021-04-14 Incyte Corp Schéma posologique destiné au traitement de troubles liés à la pi3k
WO2019233994A1 (en) 2018-06-04 2019-12-12 Exscientia Ltd Pyrazolopyrimidine compounds as adenosine receptor antagonists
US20220041603A1 (en) * 2018-09-18 2022-02-10 Societe Des Produits Nestle S.A. Src inhibitor compounds for skeletal muscle modulation, methods and uses thereof
US20210347780A1 (en) * 2018-09-19 2021-11-11 Vyera Pharmaceuticals, LLC Cdpk1 inhibitors, compositions, and methods related thereto
KR102706457B1 (ko) * 2018-12-06 2024-09-11 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
BR112021012950A2 (pt) * 2019-01-03 2021-09-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Métodos e materiais para aumentar os níveis de polipeptídeo do fator de transcrição eb
KR20230096026A (ko) * 2020-10-23 2023-06-29 일동제약(주) Cftr 조절제 화합물, 그의 조성물 및 용도
WO2022133480A1 (en) * 2020-12-18 2022-06-23 Ikena Oncology, Inc. Aryl hydrocarbon receptor (ahr) agonists and uses thereof
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
WO2022185253A1 (en) * 2021-03-03 2022-09-09 Instytut Biologii doswiadczalnej imienia Marcelego Nenckiego Polskiej Akademii Nauk Inhibitor of protein kinase d for use in prevention or treatment of hyperlipidemia
CN116514845A (zh) * 2022-01-22 2023-08-01 轩竹生物科技股份有限公司 Usp1抑制剂及其用途
EP4461732B1 (en) * 2023-05-09 2025-07-30 Molecular Horizon S.r.l. Phenylpyrazole insecticide compounds and compositions
WO2025121320A1 (ja) * 2023-12-04 2025-06-12 国立大学法人山口大学 多発性嚢胞腎の予防又は治療剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342501B1 (en) * 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
CA2450777C (en) * 2001-08-10 2013-04-09 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
WO2003082341A1 (en) * 2002-03-22 2003-10-09 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO[3,4-d] PYRIMIDINES AS KINASE MODULATORS
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
JP2007505158A (ja) * 2003-05-21 2007-03-08 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2005112936A1 (en) * 2004-05-14 2005-12-01 The Regents Of The University Of Michigan Compositions and methods relating to protein kinase inhibitors
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
JP2008520744A (ja) * 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
US20090270431A1 (en) * 2005-10-19 2009-10-29 The University Of Georgia Research Foundation Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
WO2007126841A2 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
WO2008147687A1 (en) * 2007-05-21 2008-12-04 Mayo Foundation For Medical Education And Research Treating pancreatitis

Also Published As

Publication number Publication date
EP2217239A2 (en) 2010-08-18
CN101917999A (zh) 2010-12-15
US20100331297A1 (en) 2010-12-30
WO2009062118A2 (en) 2009-05-14
CA2705303A1 (en) 2009-05-14
AU2008323694A1 (en) 2009-05-14
WO2009062118A3 (en) 2009-12-30
EA201070572A1 (ru) 2010-12-30
JP2011503103A (ja) 2011-01-27
ZA201003725B (en) 2011-03-30

Similar Documents

Publication Publication Date Title
BRPI0820342A2 (pt) Modulação de tráfego de proteína
DK3118220T3 (da) Protein
EP2215246A4 (en) PROTEIN SCAFFOLDS
DE602008000428D1 (de) Verkehrsinformationssystem
BRPI0820942A2 (pt) Estimativa de tráfico de televisão
DK2046826T3 (da) Exendin-fusionsproteiner
BRPI0818380A2 (pt) Combinação de herbicida-protetor
BRPI0813653A2 (pt) Compostos de imidazotiazol moduladores de sirtuína
BRPI0813651A2 (pt) Compostos de tiazolopiridina moduladores de sirtuína
DE602008001392D1 (de) Fahrzeuglampe
EP2201569A4 (en) CONFIGURATION CONTEXT CHANGER
ES2752025T8 (es) Métodos de cribado de proteínas
BRPI0814971A2 (pt) Proteína
DE602008000562D1 (de) Fahrzeugrad
BRPI0811014A2 (pt) Veículo
DE602008001297D1 (de) Fahrzeugrad
EP1841794A4 (en) MODULATORS ADAM-9
BRPI0815203A2 (pt) gel contendo pirfenidona
EP2192916A4 (en) MODULATION OF SYNAPTOGENESIS
BRPI0816624A2 (pt) Sapata de trilho ferroviário
DE602008000034D1 (de) Rollerartiges Fahrzeug
NO2022038I1 (no) ropeginterferon alfa-2b
BRPI0813556A2 (pt) Termoestabilização de proteínas
BRPI0810195A2 (pt) Moduladores de gpbar1
FR2922628B1 (fr) Lampadaire

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.